IBio, Common Valuation
| IBIO Stock | USD 5.08 0.05 0.97% |
At this time, the entity appears to be overvalued. iBio, Common Stock retains a regular Real Value of $4.52 per share. The prevalent price of the entity is $5.08. Our model calculates the value of iBio, Common Stock from examining the entity fundamentals such as Return On Asset of -0.3, shares outstanding of 9.14 M, and Current Valuation of 47.15 M as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting IBio, Common's valuation include:
Price Book 3.6102 | Enterprise Value | Enterprise Value Ebitda (1.59) | Price Sales 133.769 | Enterprise Value Revenue 125.7209 |
Overvalued
Today
Please note that IBio, Common's price fluctuation is very risky at this time. Calculation of the real value of iBio, Common Stock is based on 3 months time horizon. Increasing IBio, Common's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since IBio, Common is currently traded on the exchange, buyers and sellers on that exchange determine the market value of IBio, Stock. However, IBio, Common's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.08 | Real 4.52 | Target 4.3 | Hype 5.11 |
The intrinsic value of IBio, Common's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence IBio, Common's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of iBio, Common Stock helps investors to forecast how IBio, stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IBio, Common more accurately as focusing exclusively on IBio, Common's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use IBio, Common's intrinsic value based on its ongoing forecasts of IBio, Common's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against IBio, Common's closest peers.
IBio, Common Cash |
|
IBio, Valuation Trend
Knowing IBio, Common's actual value is paramount for traders when making sound investment determinations. Using both IBio, Common's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
IBio, Revenue by Product
IBio, Common Total Value Analysis
iBio, Common Stock is currently forecasted to have valuation of 47.15 M with market capitalization of 23.3 M, debt of 4.46 M, and cash on hands of 33.52 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the IBio, Common fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
47.15 M | 23.3 M | 4.46 M | 33.52 M |
IBio, Common Investor Information
About 32.0% of the company shares are owned by institutional investors. The book value of IBio, Common was currently reported as 2.47. The company recorded a loss per share of 4.03. iBio, Common Stock last dividend was issued on the 11th of June 2018. The entity had 1:20 split on the 29th of November 2023. Based on the analysis of IBio, Common's profitability, liquidity, and operating efficiency, iBio, Common Stock may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.IBio, Common Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. IBio, Common has an asset utilization ratio of 0.78 percent. This suggests that the Company is making $0.00783 for each dollar of assets. An increasing asset utilization means that iBio, Common Stock is more efficient with each dollar of assets it utilizes for everyday operations.IBio, Common Ownership Allocation
The market capitalization of IBio, Common is $23.3 Million. 30% of iBio, Common Stock outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Accordingly, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the entity is larger than the current market value, you may still be able to generate positive returns on investment in this company.IBio, Common Profitability Analysis
The company reported the previous year's revenue of 225 K. Net Loss for the year was (24.91 M) with profit before overhead, payroll, taxes, and interest of 2.17 M.About IBio, Common Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of iBio, Common Stock. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of iBio, Common Stock based exclusively on its fundamental and basic technical indicators. By analyzing IBio, Common's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of IBio, Common's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of IBio, Common. We calculate exposure to IBio, Common's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IBio, Common's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 258.8 K | 245.8 K | |
| Pretax Profit Margin | (78.93) | (74.98) | |
| Operating Profit Margin | (85.02) | (80.77) | |
| Net Loss | (127.30) | (120.94) | |
| Gross Profit Margin | 0.82 | 0.46 |
IBio, Common Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 3.8 M |
IBio, Common Current Valuation Indicators
IBio, Common's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final IBio, Common's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as IBio, Common, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use IBio, Common's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes IBio, Common's worth.When determining whether iBio, Common Stock offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IBio, Common's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ibio, Common Stock Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ibio, Common Stock Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IBio, Common. If investors know IBio, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IBio, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth (0.88) | Return On Assets | Return On Equity |
The market value of iBio, Common Stock is measured differently than its book value, which is the value of IBio, that is recorded on the company's balance sheet. Investors also form their own opinion of IBio, Common's value that differs from its market value or its book value, called intrinsic value, which is IBio, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IBio, Common's market value can be influenced by many factors that don't directly affect IBio, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IBio, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.